Nurix Therapeutics (NRIX) Change in Acquisitions & Divestments (2020 - 2026)

Nurix Therapeutics (NRIX) has reported Change in Acquisitions & Divestments for 7 consecutive years, with $119.6 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Change in Acquisitions & Divestments fell 16.0% year-over-year to $119.6 million; the TTM figure through May 2026 stood at $588.7 million (up 6.68% YoY), while the FY2025 annual figure was $617.5 million, up 34.39% from the prior year.
• Change in Acquisitions & Divestments fell to $119.6 million in Q2 2026 per NRIX's latest filing, from $133.2 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $179.8 million in Q4 2025 and bottomed at $41.0 million in Q1 2023.
• Historically, Change in Acquisitions & Divestments has averaged $107.3 million across 5 years, with a median of $102.7 million in 2023.
• Annual changes were most pronounced in 2023 — Change in Acquisitions & Divestments slumped 30.23% — and 2024, when it soared 127.39%.
• Nurix Therapeutics' Change in Acquisitions & Divestments stood at $84.5 million in 2022, then decreased by 9.33% to $76.6 million in 2023, then jumped by 108.21% to $159.5 million in 2024, then grew by 12.73% to $179.8 million in 2025, then tumbled by 33.51% to $119.6 million in 2026.
• Business Quant data shows NRIX's Change in Acquisitions & Divestments at $119.6 million in Q2 2026, $133.2 million in Q1 2026, and $179.8 million in Q4 2025.